Pınar KADIOĞLU, Serdar ŞAHİN, Emre DURCAN, Hande Mefkure ÖZKAYA, Gular KARİMOV, Şeyda Gül ÖZCAN

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience

Background/aim: Cushing’s disease (CD), which cannot be controlled by surgery, requires medical treatment. In this situation, treatments with long-term effectiveness and safety profiles are needed. We aimed to evaluate the effects and adverse effects of pasireotide treatment in CD. Materials and methods: Patients who were followed up for CD and treated with pasireotide between 2014–2020 at Cerrahpaşa Medical Faculty, were evaluated retrospectively. The efficacy and adverse effects of pasireotide were evaluated in this study. Results: Thirty-two patients were evaluated. The mean duration of treatment was 26.5 [range, 12.0–37.0] months. The 24-h urinary free cortisol (UFC) decreased 46% during the treatment and normalized in 37.5% of patients. A significant decrement was found between pretreatment and last follow-up UFC (p = 0.001). Plasma ACTH decreased by 21%. A significant decrement was found between pre-treatment and the 3rd month, 6th month, and last follow-up ACTH levels (p = 0.014, p = 0.017, and p = 0.017, respectively). Serum cortisol levels decreased by 18% and a significant decrement was found between pretreatment and the 3rd month, and between pretreatment and the last follow-up (p = 0.034 and p = 0.013, respectively). While fasting blood glucose at the 3rd month was significantly higher than pretreatment fasting blood glucose, no significant difference was found between pretreatment fasting blood glucose and 6th month and last follow-up fasting blood glucose. Although there was a significant difference between pretreatment HbA1c levels and the HbA1c levels at the 3rd month (5.9% vs. 6.6% p = 0.007), 6th month (5.9% vs. 6.7% p = 0.003), and the last follow-up (5.9% vs. 7.1% p = 0.001), in the last follow-up, the majority (77%) of patients had adequate glycemic control (HbA1c ≤ 7.0 %). Conclusion: Pasireotide treatment is an alternative treatment in CD, remission is obtained in the first months of treatment, and continues for an extended period. Although hyperglycemia is the most common adverse effect, it can be successfully controlled.

PDF

___

1. Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J et al. Treatment of cushing’s syndrome: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2015; 100(8):2807-2831. doi:10.1210/jc.2015-1818
2. Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P et al. Incidence and late prognosis of Cushing’s syndrome: A population-based study. Journal of Clinical Endocrinology and Metabolism 2001; 86(1):117-123. doi:10.1210/jc.86.1.117
3. Arnardóttir S, Sigurjonsdóttir HA. The incidence and prevalence of Cushing’s disease may be higher than previously thought: Results from a retrospective study in Iceland 1955 through 2009. Clinical Endocrinology 2011; 74(6):792-793. doi:10.1111/j.1365- 2265.2010.03961.x
4. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clinical Endocrinology 2011; 75(4):436-442. doi:10.1111/j.1365 2265.2011.04124.x
5. Newell-Price J, Trainer P, Besser M, Grossman A. The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and PseudoCushing’s States. Endocrine Reviews 1998; 19(5):647-672. doi:10.1210/edrv.19.5.0346
6. Giraldi FP, Moro M, Cavagnini F. Gender-related differences in the presentation and course of Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 2003; 88(4):1554-1558. doi:10.1210/jc.2002-021518
7. Lonser RR, Nieman L, Oldfield EH. Cushing’s disease: Pathobiology, diagnosis, and management. Journal of Neurosurgery 2017; 126(2):404-417. doi:10.3171/2016.1.JNS152119
8. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 Years in Stoke-onTrent, UK: Audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism 2011; 96(3):632-642. doi:10.1210/jc.2010-1942
9. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: An epidemiological approach. Clinical Endocrinology 1994; 40(4):479-484. doi:10.1111/j.1365-2265.1994.tb02486.x
10. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JOL. Mortality in Cushing’s syndrome: A systematic review and meta-analysis. European Journal of Internal Medicine 2012; 23(3):278-282. doi:10.1016/j.ejim.2011.10.013
11. Van Haalen FM, Broersen LHA, Jorgensen JO, Pereira AM, Dekkers OM. Management of endocrine disease: Mortality remains increased in Cushing’s disease despite biochemical remission: A systematic review and meta-analysis. European Journal of Endocrinology 2015; 172(4): R143-149. doi:10.1530/EJE-14-0556
12. Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK et al. Mortality in patients with Cushing’s disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study. The Lancet Diabetes and Endocrinology 2016; 4(7):569-576. doi:10.1016/S2213-8587(16)30005-5
13. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET et al. Transsphenoidal microsurgery for Cushing’s disease: Initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 2004; 89(12):6348-6357. doi:10.1210/jc.2003-032180
14. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing’s disease: The need for long-term surveillance. Clinical Endocrinology 2005; 63(5):549-559. doi:10.1111/ j.1365-2265.2005.02380.x
15. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. Journal of Clinical Endocrinology and Metabolism 2008; 93(2):358-362. doi:10.1210/jc.2007- 2013
16. Aranda G, Enseñat J, Mora M, Puig-Domingo M, Martínez de Osaba MJ et al. Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up. Pituitary 2015; 18(1):142-149. doi:10.1007/s11102-014-0567-8
17. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X et al. Treatment of adrenocorticotropin-dependent cushing’s syndrome: A consensus statement. Journal of Clinical Endocrinology and Metabolism 2008; 93(7):2454-2462. doi:10.1210/jc.2007-2734
18. Ambrogio AG, Cavagnini F. Role of “old” pharmacological agents in the treatment of Cushing’s syndrome. Journal of Endocrinological Investigation 2016; 39(9):957-965. doi:10.1007/s40618-016-0462-4
19. Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J et al. Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: Care reality in the munich metropolitan region. European Journal of Endocrinology 2014; 21;170(2):283-292. doi:10.1530/EJE-13-0634
20. Gadelha MR, Neto LV. Efficacy of medical treatment in Cushing’s disease: A systematic review. Clinical Endocrinology 2014; 80(1):1-12. doi:10.1111/cen.12345
21. Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary radiotherapy for Cushing’s disease. Neuroendocrinology 2010; 92 Suppl 1:107-110. doi:10.1159/000314299
22. Van der Hoek J, Waaijers M, Van Koetsveld PM, Sprij-Mooij D, Feelders RA et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. American Journal of Physiology-Endocrinology and Metabolism 2005; 289(2): E278-287
23. Van der Hoek J, Lamberts SWJ, Hofland LJ. The role of somatostatin analogs in Cushing’s disease. Pituitary 2004; 7(4): 257-264.doi: 10.1007/s11102-005-1404-x
24. Bruin C de, Feelders RA, Lamberts SWJ, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord 2008; 10(2):91- 102. doi:10.1007/s11154-008-9082-4
25. Cuevas-Ramos D, Fleseriu M. Treatment of Cushing’s disease: a mechanistic update. J Endocrinol 2014; 223(2): R19-39. doi:10.1530/JOE-14-0300
26. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH et al. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Comm. Journal of Clinical Hypertension 2014; 32(1):3-15. doi:10.1111/jch.12237
27. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. New England Journal of Medicine 2012; 8;366(10):914-924. doi:10.1056/nejmoa1105743
28. Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G et al. Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 2017; 57(1):156-165. doi:10.1007/s12020-017-1316-3
29. Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 2015; 18(5):604-612. doi:10.1007/s11102-014-0618-1
30. Trementino L, Michetti G, Angeletti A, Marcelli G, Concettoni C et al. A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome. Hormone and Metabolic Research 2016; 48(5):290-298. doi:10.1055/s-0042-101347
31. Fleseriu M, Iweha C, Salgado L, Mazzuco TL, Campigotto F et al. Safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: Results from an open-label, multicenter, single-arm, multinational, expanded-access study. Frontiers in Endocrinology 2019; 16; 10:436. doi:10.3389/fendo.2019.00436
32. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: Clinical and health-related quality of life aspects. European Journal of Endocrinology 2012; 167(3):311- 326. doi:10.1530/EJE-11-1095
33. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D et al. Persistence of increased cardiovascular risk in patients with cushing’s disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999; 84(8):2664- 2672. doi:10.1210/jcem.84.8.5896
34. Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: Results from a Phase III study. Clinical Endocrinology 2014; 81(3):408-417. doi:10.1111/cen.12431
35. Simeoli C, Ferrigno R, De Martino MC, Iacuaniello D, Papa F et al. The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. Journal of Endocrinological Investigation 2020; 43(1):57-73. doi:10.1007/s40618-019-01077-8
36. Yedinak CG, Hopkins S, Williams J, Ibrahim A, Cetas JS et al. Medical therapy with pasireotide in recurrent Cushing’s disease: Experience of patients treated for at least 1 year at a single center. Frontiers in Endocrinology 2017; 27; 8:35. doi:10.3389/fendo.2017.00035
37. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M et al. Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 2013; 98(8):3446- 3453. doi:10.1210/jc.2013-1771
38. Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Research and Clinical Practice 2014; 103(3):458-465. doi:10.1016/j. diabres.2013.12.011
39. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. Journal of Endocrinological Investigation 2012; 35(4):434-448. doi:10.1007/BF03345431